Search

356 Result(s)
Sort by

Ridgefield Research and Innovation

Ridgefield Research and Innovation

Ridgefield, CT, USA is Boehringer Ingelheim's 3rd largest research sit, where scientists are tackling some of the most difficult challenges in healthcare.
Clinical Development and Operations

Clinical Development and Operations

Click here to find out more on how Boehringer Ingelheim is proud to offer a new 2-year Fellowship program within Clinical Operations.
The Core of our Leitbild

The Core of our Leitbild

Click here to find out more about Boehringer Ingelheim's core values and mission statement, highlighting our key business focuses.
From the archives: Maria Plum’s story as a pioneer of her time

From the archives: Maria Plum’s story as a pioneer of her time

Maria Plum was one of the first female lawyers in Germany, and she served as legal counselor for our company starting in the 1930s. Read account of her story written by Katrin Lege, Head of the Boehringer Ingelheim Company Archives, who discovered details
Family owned

Family owned

Did you know that Boehringer is still family-owned? Read this article to learn more about our culture. Check out our Careers Page for more talent insights!
Victor Emenike

Victor Emenike

Victor Emenike is a data scientist in operations, specifically in the launch and innovation organization, feels valued and supported in new ideas.
Accessibility Statement

Accessibility Statement

Boehringer Ingelheim endeavors to make https://www.boehringer-ingelheim.com accessible to any and all users.
Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death